ClinicalTrials.gg
RecruitingNCT07241221AMuletUpdated Dec 9, 2025

Antenatal Myo-inositol Supplementation in Pre-existing Diabetes

An interventional study of Myo-inositol and folic acid supplement and Folic acid supplement in Perinatal and Neonatal Outcomes in Pregnancies With Type 2 Diabetes Mellitus (T2DM), sponsored by National University Hospital, Singapore. Recruiting at 1 site in Singapore. Open to female participants aged 21 Years to 45 Years. Per ClinicalTrials.gov, last updated 2025-12-09.

Sponsored by National University Hospital, Singapore · Not applicable, Interventional, and Supportive care

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
182
Allocation
Randomized
Ages
21 Years to 45 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 89 studies in Diabetes Mellitus with a site in Singapore — 10 open to participants now, 15 under way, none of them phase 3. Diabetes Mellitus · Singapore.

Planned enrollment
32nd of 73
182 · median 137
Started
2025
with 2 others
No phase
50 of 89
8 open now
Primary completion
2028-08
later than 11 of 14 live
Registered
86th of 89
by date

Among the 89 studies in Diabetes Mellitus with a site in Singapore, this one is the 32nd largest by planned enrollment of the 73 interventional ones that give a count, is one of 3 that started in 2025, is one of 50 with no phase, reaches primary completion later than 11 of the 14 other live ones, and was the 86th registered.

Diabetes Mellitus

8,295 studies on the registry are indexed under Diabetes Mellitus; 1,071 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

10 of the 89 studies in Diabetes Mellitus with a site in Singapore are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in Singapore have not opened yet or have stopped. Only those recruiting at a site in Singapore →

Who these studies take

Of the 649 Diabetes Mellitus studies recruiting now, 358 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.

This study: 21 Years to 45 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 89 studies in Diabetes Mellitus with a site in Singapore, or all of them as a file.
02

Study summary

This feasibility pilot study aims to gather data that can guide the design of a larger, more comprehensive trial to establish the effects of myo-inositol supplementation on supporting healthy outcomes in pregnancies complicated by Type 2 Diabetes Mellitus (T2DM). It seeks to assess myo-inositol's potential to support fetal and neonatal health, and optimise maternity outcomes as a complementary approach and adjuvant to existing diabetes mellitus therapies, as well as investigate the underlying biological mechanisms.

Read the detailed description

The "Antenatal Myo-inositol supplementation in pre-existing diabetes to promote normal neonatal outcomes (AMulet)" pilot study aims to inform the design of a future double-blind randomised controlled trial which can assess the benefits of myo-inositol supplementation in pregnant women with T2DM. Despite provision of the international standard of care, pregnancies complicated by diabetes remain at high risk of adverse perinatal and neonatal outcomes. Offspring exposed to maternal diabetes in-utero also face increased risks of obesity and cardiometabolic diseases later in life. Myo-inositol supplementation has been trialled in pregnancy for the prevention and treatment of gestational diabetes, as well as in non-pregnant adults with T2DM, where improvements in glycaemic regulation and reduced insulin resistance have been observed with supplementation. However, myo-inositol supplementation has not yet been studied in pregnancies with T2DM. The primary aim of the AMulet trial would be to assess whether myo-inositol supplementation in pregnancies with T2DM can support normal fetal size and neonatal wellbeing. The present AMulet pilot study will assess the feasibility and acceptability of conducting such a trial and, additionally, seek to investigate the biological mechanisms through which myo-inositol may influence maternal and offspring health outcomes.

This pilot will recruit 182 pregnant women with T2DM between 12-16 weeks' gestation into a double-blind placebo-controlled randomized study. All participants will be randomly assigned to either an intervention group (receiving supplementation of myo-inositol with folic acid) or a control group (receiving supplementation with folic acid only). Supplementation will be in the form of similar looking capsules to be taken twice daily from recruitment until delivery.

Data and samples will be collected longitudinally across three study visits during pregnancy that will be arranged to coincide with routine antenatal clinic visits where possible, and a fourth visit soon after delivery. Additionally, there will be two re-supply visits and a post-delivery videoconference call. Other study data comprising antenatal, peripartum, fetal and neonatal outcomes will be extracted from medical records during pregnancy and post-delivery to assess the primary and secondary outcomes.

The binary composite primary outcome of normal fetal/neonatal size and wellbeing will be assessed by analyses on an intention-to-treat basis. Secondary outcomes, comprising maternity and other infant outcomes, will be assessed and quantified in terms of relative risk or mean differences between study groups. Adverse events, participant feedback as well as mechanistic understanding will be obtained.

This structured approach will inform the design of a future RCT by gathering data on feasibility and acceptability, identifying potential issues in protocols and data collection tools, and facilitating sample size calculations for the main trial which will aim to support the optimization of maternal and offspring health outcomes in pregnancies complicated by pre-existing T2DM.

03

Conditions studied

  • Perinatal and Neonatal Outcomes in Pregnancies With Type 2 Diabetes Mellitus (T2DM)

Keywords

  • Diabetes
  • Pregnancy
  • Myo-inositol
  • Folic acid
  • Dietary Supplement
  • Birthweight
  • Prematurity
  • Neonatal Intensive Care Unit Admission
  • Stillbirth
  • Neonatal Death
  • Neonatal Complications
  • Maternity Complications
04

Who can participate

Ages eligible
21 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pregnant women aged 21 years to 45 years old at the time of recruitment
  • Ongoing, viable, singleton intrauterine pregnancy
  • Between 12+0 days-16+6 days weeks' gestation at recruitment
  • T2DM diagnosed by a documented 75g Oral Glucose Tolerance Test (OGTT) showing a fasting glucose of >7 mmol/L or 2h glucose >11.1 mmol/L, or an >6.5%, either prior to pregnancy or during the first 16 weeks of the index pregnancy
  • Intend to receive antenatal care and give birth at NUH
  • Willing to provide written,
  • Able to swallow capsules and comply with trial procedures

Exclusion criteria

Exclusion Criteria

  • Known or suspected fetal aneuploidy or genetic/structural anomaly
  • Severe allergy to food items requiring carriage of an Epipen at all times
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
182 participants (estimated)

Study arms

  • Experimental
    Intervention (myo-inositol and folic acid supplement)

    Participants in the intervention arm will receive a total of 4 g/day of myo-inositol and 300 mcg/day of folic acid, divided into two daily doses.

    Dietary Supplement: Myo-inositol and folic acid supplement

  • Active comparator
    Control (folic acid supplement)

    Participants in the control arm will receive a total of 300 mcg/day of folic acid, divided into two daily doses.

    Dietary Supplement: Folic acid supplement

Interventions

  • Dietary supplementMyo-inositol and folic acid supplement

    Participants will take 4 capsules in the morning and 4 capsules in the evening, each capsule containing 500 mg of myo-inositol and 37.5 mcg of folic acid. Capsules are to be swallowed whole with a drink, starting from 12-16 weeks' gestation and continued until delivery.

  • Dietary supplementFolic acid supplement

    Participants will take 4 capsules in the morning and 4 capsules in the evening, each capsule containing 37.5 mcg of folic acid. Capsules are to be swallowed whole with a drink, starting from 12-16 weeks' gestation and continued until delivery.

06

What researchers measure

Primary outcomes

  1. Composite of fetal/neonatal wellbeing

    Number and proportion of cases displaying all of the following outcomes of (1) being appropriately-grown-for-gestational-age (AGA; 10th-90th centile in weight) at birth; (2) delivered at term (37 weeks+0 days gestation or more); (3) no admission to the neonatal unit in the first 4 weeks of life; and (4) alive at delivery and at 4 weeks post-delivery. Results will also be presented as a relative risk with 95% confidence intervals, with and without adjustment for important covariates, as well as with and without stratification for baseline HbA1C (high/low), pre-pregnancy insulin treatment, duration since T2DM diagnosis (\<1y, \>1y), and in per-protocol analyses.

    Time frame: From birth until 4 weeks post-delivery

Secondary outcomes

  1. Intrauterine fetal growth and wellbeing as assessed by antenatal serial ultrasound scans

    Mean differences in cross-sectional comparisons and longitudinal changes in measured biometric parameters, derived size/weight estimates and Doppler assessments, as well as differences in the velocity of growth, peak/nadir in the velocity of growth and its gestational timing, and the fastest/slowest change in growth velocity and its gestational timing, with and without adjustment for important covariates.

    Time frame: Up to 38 weeks duration, from the earliest scan in pregnancy ~5-6 weeks' gestation until delivery of the baby between 22-42 weeks' gestation.

  2. Neonatal anthropometry and body composition

    Number and proportion, and relative risks, of macrosomia (birthweight \>4000 g), low birthweight (\<2500 g), Large-for-Gestational-Age (LGA; birthweight \>90th centile), and Small-for-Gestational-Age (SGA; birthweight \<10th centile), and mean differences or categorically-defined outcomes of birthweight, birth length, head circumference, abdominal circumference, mid-arm circumference, skinfold thickness, fat mass, fat-free mass, and percentage body fat (assessed by air displacement plethysmography, PEAPOD), with and without adjustment for important covariates. Continuous data to be standardised to z-scores, where appropriate.

    Time frame: Birth till 4-6 weeks post-delivery

  3. Other perinatal and neonatal outcomes

    Number and proportion, and relative risks, of neonatal respiratory distress (aetiology and treatment required), neonatal hypoglycemia, number of hypocount values \<2.6 mmol/L, hyperbilirubinemia requiring phototherapy or exchange transfusion, neonatal sepsis (early and late onset, aetiology and treatment required), shoulder dystocia, birth trauma, hypoxic ischaemic encephalopathy/intracranial haemorrhage, neonatal unit admission, or stillbirth/neonatal death, as well as mean differences in the levels of glycaemia and bilirubinaemia, and in the duration of respiratory support, phototherapy and neonatal unit/hospital stay, with and without adjustment for important covariates. Continuous data to be standardised to z-scores, where appropriate.

    Time frame: Birth till 4-6 weeks post-delivery

  4. Fetal (cord) insulinaemia and C-peptide

    Number and proportion, and relative risks of fetal hyperinsulinaemia or high C-peptide concentration, and mean difference in insulin or C-peptide concentrations in umbilical cord blood (where obtainable); with and without adjustment for important covariates

    Time frame: At birth

  5. Maternal glycaemic control

    Mean differences and change in blood glucose levels (monitored through self-blood glucose monitoring or continuous glucose monitoring, CGM), other CGM parameters, markers of glycemic control, the frequency of participant-managed hypoglycemic episodes, proportional increases in metformin or insulin doses, and mean differences in daily insulin requirements per kilogram (kg) of body weight, proportion requiring other diabetes treatments, mean differences and change in HbA1C and HOMA-IR; with and without adjustment for important covariates. Continuous data to be standardised to z-scores, where appropriate.

    Time frame: Up to 100 weeks duration, from within a year before conception (last recorded before conception) or early pregnancy (between conception and recruitment between ~12-16 weeks gestation), until the delivery of the baby (between 22-42 weeks gestation).

  6. Hypertensive disorders of pregnancy

    Number and proportion, and relative risks, of pre-eclampsia/eclampsia, superimposed pre-eclampsia on chronic hypertension, and pregnancy-induced hypertension (as a composite and as individual complications), as well as difference in the gestational age of onset or diagnosis and severity of disorder, with and without adjustment for important covariates.

    Time frame: Between time of recruitment (~12 to 16 weeks of gestation) and 4-6 weeks post-delivery

  7. Gestational age at delivery and preterm prelabour rupture of membranes (PPROM)

    Number and proportion, and relative risks, of PPROM and preterm delivery (spontaneous and/or iatrogenic births), reasons for preterm birth, as well as the gestational ages at delivery and at PPROM will be presented, with and without adjustment for important covariates.

    Time frame: Between time of recruitment (~12 to 16 weeks of gestation) and delivery

  8. Gestational weight gain

    Mean differences in the total weight a woman gains during pregnancy, measured in kilograms (kg), as well as the rate of weight gain over the second and third trimesters of pregnancy (kg/week). Proportional differences in the categorisation of weight gain by the Institute of Medicine (IOM) guidelines as insufficient, appropriate, or excessive (considering the mother's pre-pregnancy BMI), with and without adjustment for important covariates

    Time frame: Up to 100 weeks duration; From pre-pregnancy (last recorded weight before conception) or earliest recorded weight in pregnancy (between conception and recruitment) to the last recorded weight before delivery (22-42 weeks gestation).

  9. Maternal depressive and anxiety symptoms

    Mean differences and change from baseline in scores of maternal depression and anxiety symptoms on validated questionnaires (Edinburgh Postnatal Depression Scale and State-Trait Anxiety Inventory), and proportional differences between groups in those with higher and lower scores, with and without adjustment for important covariates. Continuous data to be standardised to z-scores, where appropriate.

    Time frame: Between time of recruitment (~12 to 16 weeks of gestation) and 4-6 weeks post-delivery

  10. Mode of delivery

    Number and proportion, and relative risks, of caesarean section, primary caesarean section, emergency caesarean section, and instrumental delivery, with and without adjustment for important covariates.

    Time frame: At delivery

  11. Postpartum blood loss

    Number and proportion, and relative risks, of major postpartum haemorrhage (primary and secondary), and mean differences in the volume of blood loss (primary and secondary), with and without adjustment for important covariates.

    Time frame: At delivery and up to 4-6 weeks post-delivery

  12. Other antenatal and peripartum events

    Number and proportion, and relative risks, of antenatal complications such as intrahepatic cholestasis, placental abruption and antepartum haemorrhage, and peripartum events encompassing type of onset/induction and progress of labour, requirement for labour augmentation, non-reassuring cardiotocography suggestive of fetal compromise, meconium-stained liquor, shoulder dystocia, perineal trauma, admission to high-dependency/intensive care unit, and other relevant complications, as well as mean differences in the duration of each stage of labour and entire labour, and length of maternal HDU/ICU/hospital stay, with and without adjustment for important covariates.

    Time frame: From conception to 4-6 weeks post-delivery

  13. Circulating, urinary and placental inositol and inositol-metabolite concentrations

    Mean differences in cross-sectional comparisons and longitudinal changes from baseline in maternal circulation and urinary concentrations of myo-inositol and the other 4 inositol isomers, and inositol metabolites, as well as mean differences in circulating fetal/cord concentrations of these inositols/inositol-metabolites at birth, and in placental and fetal membrane tissues; with and without adjustment for important covariates.

    Time frame: Between time of recruitment (~12 to 16 weeks of gestation) and delivery

  14. Multi-Omic Profiling

    Differences in the characteristics and quantities of each element/class of the biochemical, metabolic, metabolomic, hormonal, chemoadipocytokine, proteomic, lipidomic, genomic, epigenomic and transcriptomic profiles as well as tissue tensile strength (where applicable) in maternal blood \& urine, fetal (umbilical cord) blood \& tissue, placenta and fetal membranes.

    Time frame: Between the time of recruitment (~12 to 16 weeks of gestation) and delivery

  15. Stool microbiota composition and activity

    Descriptive and quantifiable differences in metagenomics and metatranscriptomics, reflecting microbial diversity, the relative abundance of key bacterial species, and metabolic activity in maternal and neonatal stool. Continuous data to be standardised to z-scores, where appropriate.

    Time frame: Between the time of recruitment (~12 to 16 weeks of gestation) and 4-6 weeks post-delivery

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2025; primary completion for Aug 2028, 32 months later.

Of 1,590 non-industry interventional studies with no phase under Diabetes Mellitus, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 32 months is above that.

Counting every sponsor, half of 1,750 studies reached it within 21 months; a quarter within 9 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 18, 2025
First posted
Nov 21, 2025
StartEst.
Dec 2025
Primary completionEst.
Aug 31, 2028
CompletionEst.
Aug 31, 2029
Last update
Dec 9, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07241221
Responsible party
Sponsor
First posted
Nov 21, 2025
Start date
Dec 2025 (estimated)
Primary completion
Aug 31, 2028 (estimated)
Completion
Aug 31, 2029 (estimated)
Last update
Dec 9, 2025

Study contacts

Gladys Woon, Bsc
Contact
gladys_woon@nuhs.edu.sg
+65 6516 4134
Shiao-Yng Chan, MBBChir (UK), FRCOG (UK), PhD
principal investigator · National University of Singapore, National University Hospital Singapore, Institute for Human Development and Potential (A*STAR)

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion